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Abstract
Background: This study evaluated the distribution pattern of the Ki67-labeling index (LI) among patients at a Chinese
breast cancer center, and analyzed its prognostic significance in the 2015 St Gallen consensus breast cancer classification,
estrogen receptor-positive and human epidermal growth factor receptor 2-negative(ER+/HER2−)subtype.
Methods: We classified 939 women with ER+/HER2− breast cancer into three groups by Ki67-LI levels, and followed their
clinicopathologic characteristics and prognoses.
Results: In the 939 eligible subjects, 342 had Ki67-LI ≤10% (Ki67Low), 281 had Ki67-LI between 10 and 30% (Ki67Medium),
and 316 had Ki67-LI ≥30% (Ki67High). Although the Ki67High group had less favorable clinicopathologic factors, the
Ki67Medium group’s factors varied considerably. Kaplan-Meier estimates showed that disease-free survival(DFS) for the
Ki67Medium group was significantly shorter than the Ki67Low group but longer than the Ki67High group. Ki67-LI had
independent prognostic significance in multivariate analysis. Other diagnostic factors, including tumor size >2 cm,
positive lymph nodes, and grade III disease, were significantly associated with poorer disease-free survival only in the
Ki67Medium group.
Conclusions: For patients with ER+/HER2− breast cancer, we confirmed three distinct risk patterns by Ki67-LI levels
according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions
could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information.
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Background
Breast cancer (BC) is a molecularly heterogeneous dis-
ease that includes at least four intrinsic subtypes with
different features and prognoses [1–5]. Among estrogen
receptor-positive and human epidermal growth factor
receptor 2-negative (ER+/HER2−) BCs, gene expression-
based assays showed that they can be divided into at least
two distinct subgroups—luminal A and luminal B [4]. Al-
though the luminal B subset has higher proliferation
marker expression and worse prognosis [6], clinicopatho-
logical subtyping criteria of the two luminal groups keep
changing in the literature.
The 2011 St Gallen consensus panel [7] recommended
a cut-off of 14% for the Ki67-labeling index (LI) as the
threshold between luminal A and B subtypes. The
2013 St Gallen consensus panel added another immuno-
histochemical (IHC) surrogate marker—progesterone re-
ceptor (PgR)—and increased the Ki67-LI cut-off to 20%
[8]. However, at the latest 2015 St Gallen International
Breast Cancer Conference, the panel recommended
Ki67-LI should be interpreted upon local laboratory
values, and ER+/HER2− BCs could not be classified as
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two distinctive groups by IHC surrogate markers, as they
belong to a spectrum of disease [9].
This study evaluated Ki67-LI distribution in a Chinese
BC treatment center and analyzed its prognostic signifi-
cance in the 2015 St Gallen consensus of ER+/HER2− BCs.
Methods
Patients and clinical data collection
We searched breast tumor registries of the 2063 patients
who had been treated for BC at the Sun Yat-Sen Memorial
Hospital from March 2005 to December 2012, and for
whom Ki67-LI information was available. Our hospital is
equipped with one of the most comprehensive breast cen-
ters in China, and we are highly recognized by patients
from all over the country. We excluded patients with non-
invasive BC, ER-negative or HER2-positive disease, more
than three involved lymph nodes, T4 lesions, male pa-
tients, and those with distant metastasis at first diag-
nosis. Finally, we included 939 patients with early
invasive ER+/HER2− BCs.
Of these 939 participants, 372 (39.6%) received modi-
fied radical mastectomies and 567 (60.4%) underwent
breast-conserving surgery (BCS, all with negative mar-
gins). All patients received sentinel lymph node biopsy
(SLNB), of whom SLNB positive went on to axillary
lymph node dissection(ALND). After surgery, 776
(82.6%) patients received adjuvant chemotherapy. The
regimens mainly consisted of three types: standard
cyclophosphamide, methotrexate, and 5-fluorouracil,
anthracycline-based, or combined anthracycline and tax-
ane (termed taxane-based regimen). They each received
four to eight chemotherapy cycles. The main indications
for radiotherapy included positive lymph nodes; primary
tumor >5 cm; or BCS. In our study, chemotherapy indi-
cations were based on the National Comprehensive
Cancer Network (NCCN) guidelines.
Patients were followed according to clinical protocols.
The evaluated endpoint was DFS, which was defined as
the interval from first diagnosis until diagnosis of local
or regional BC recurrence, contralateral BC, distant me-
tastasis, or death from BC. Patients known to be alive
without recurrent disease or lost to follow-up at the time
of analysis were screened at the time of their last follow-
up. For those who attended no further clinical visits at
our institute, essential follow-up information was col-
lected by telephone. The cut-off date for the results pre-
sented here was February 22, 2016. This study was
approved by the Ethics Committee of Sun Yat-Sen
Memorial Hospital, Sun Yat-Sen University.
Laboratory methods and group definition
IHC staining for ER, PgR, HER2 protein, and Ki67 antigen
was performed on core biopsies or surgical specimens. All
specimens were fixed with 10% neutral phosphate-
buffered formalin and embedded in paraffin. Samples were
considered ER+ if more than 10% nuclei were stained,
which is the usual cut-off in larger Chinese hospitals [10].
Tumors were considered HER2+ if they received a score
of three by IHC or if they were two by IHC but had ampli-
fied HER2 genes (ratio 2.0) based on fluorescence in situ
hybridization (FISH). The MIB-1 clone antibody (1:100,
DAKO) was used for Ki67 IHC staining; the Ki67-LI was
the percentage of positively stained cancer cells (regardless
of staining intensity).
Based on the 2015 St Gallen consensus standard, and
the median Ki67-LI value(20%) of patients in this study,
the 939 women were classified into three groups by cut-
off points 10 and 30% [9]. Patients whose Ki67-LI was
30% or above were considered clearly high (Ki67High);
those whose Ki67-LI was 10% or less were clearly low
(Ki67Low), and those whose Ki67-LI was 10–30% were
considered intermediate (Ki67Medium).
Statistical analysis
Statistical comparisons of clinicopathological characteris-
tics within the three groups were calculated by chi-square
and rank-sum tests. Kaplan-Meier survival curves were
calculated; log-rank test was adopted to compare DFS
within groups. Multivariate DFS analysis used the Cox
proportional hazards model. SPSS 19.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses. All P
values were two-tailed; P ≤ 0.05 was considered significant.
Results
For the 939 patients who were eligible for inclusion in
this study, the median follow-up period was 64.7 months
(range:4.3–120.7 months), and the mean follow-up
period was 67.2 months (SD:23.4 months). The Ki67-LIs
were intensively clustered at values ending with 5 or 0
(829, 88.3%). The median value of Ki67-LI was 20% for
these 939 cases. Among the 939 patients, 342 cases had
Ki67-LI ≤ 10%, 281 had Ki67-LI between 10 and 30%,
and 316 had Ki67-LI ≥ 30%. If all 2063 cases with Ki67-
LI data were included for analysis regardless of subtype,
median value increased to 25%. Ki67-LIs of this cohort
also intensively clustered at values ending with 5 or 0
(1886, 91.4%).
Table 1 shows the clinicopathological characteristics in
each group and indicates significant differences in age
distribution, menopausal status, histology, tumor size,
node involvement, grade, and PgR status. No significant
differences within groups were seen for median age or
lymphovascular invasion (LVI) status. The proportion
of early-onset BC (age <35 years) or PgR-negative/low
was higher in the Ki67High group than other groups.
Tumors <2 cm or without lymph node involvement were
more commonly observed in the Ki67Low group. Almost
all tumors in the Ki67Low group were grade I/II, whereas
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Table 1 Clinicopathologic Characteristics of three groups according to Ki67-LI level
Characteristic Ki67≤ 10%
n = 342







Associated events-no.(%) 10(2.9) 20(7.1) 49(15.5) 79(8.4)
Age
Median(IQT)-yr 49(23–86) 48(24–91) 47(22–84) 48(22–91) 0.166
Distribution-no.(%) 0.013
< 35 19(5.6) 15(5.3) 31(9.8) 65(6.9)
35–50 160(46.8) 148(52.7) 163(51.6) 471(50.2)
51–65 122(35.7) 93(33.1) 102(32.3) 317(33.8)
> 65 41(12.0) 25(8.9) 20(6.3) 86(9.2)
Menopausal status-no.(%) 0.011
Pre 171(50.0) 122(43.4) 176(55.7) 469(49.9)
Post/Peri 171(50.0) 159(56.6) 140(44.3) 470(50.0)
Histology-no.(%) <0.001
IDC 273(79.8) 236(84.0) 297(94.0) 806(85.8)
ILC 10(2.9) 10(3.6) 6(1.9) 26(2.8)
Mucinous 25(7.3) 13(4.6) 4(1.3) 42(4.5)
Other invasive histology 34(9.9) 22(7.8) 9(2.8) 65(6.9)
pT-no./total no.(%) <0.001
1 239/336(71.1) 181/276(65.6) 159/307(51.8) 579/919(63.0)
2 91/336(27.1) 86/276(31.2) 139/307(45.3) 316/919(34.4)
3 6/336(1.8) 9/276(3.3) 9/307(2.9) 24/919(2.6)
Node-no.(%) 0.022
N0 249(72.8) 180(64.1) 202(63.9) 631(67.2)
N1 93(27.2) 101(35.9) 114(36.1) 308(32.8)
LVI-no.(%) 0.074
Positive 49(14.3) 59(21.0) 61(19.3) 169(18.0)
Negative 293(85.7) 222(79.0) 255(80.7) 770(82.0)
Grade-no./total no.(%) <0.001
I/II 269/289(93.1) 189/241(78.4) 137/282(48.6) 595/812(73.3)
III 20/289(6.9) 52/241(21.6) 145/282(51.4) 217/812(26.7)
PgR-no.(%) <0.001
< 20% 58(17.0) 55(19.6) 119(37.7) 232(24.7)
≥ 20% 284(83.0) 226(80.4) 197(62.3) 707(75.3)
Surgery-no.(%) 0.479
BCS 202(59.1) 178(63.3) 187(59.2) 567(60.4)
Mastectomy 140(40.9) 103(36.7) 129(40.8) 372(39.6)
Chemotherapy-no.(%) <0.001
Yes 252(73.7) 234(83.3) 290(91.8) 776(82.6)
No 90(26.3) 47(16.7) 26(8.2) 163(17.4)
Radiotherapy-no.(%) 0.033
Yes 237(69.3) 217(77.2) 243(76.9) 697(74.2)
No 105(30.7) 64(22.8) 73(23.1) 242(25.8)
IQT interquartile range, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, LVI lymphovascular invasion, PgR progesterone receptor, BCS
breast-conserving surgery
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more than half the cases in the Ki67High group were grade
III. Nevertheless, the clinical features of the Ki67Medium
group were not remarkable, and for many cases, it was
hard to differentiate them from the Ki67Low or Ki67High
groups. The largest proportion of patients who received
chemotherapy were from the Ki67High group, and the lar-
gest proportion of patients who received radiotherapy
were from the Ki67Low group. The groups did not signifi-
cantly differ by surgery type.
A total of 79 (8.4%) patients had BC-associated disease
(Ki67Low: 10; Ki67Medium: 20; Ki67High: 49), including 12
local recurrences, seven regional nodal recurrences, three
contralateral new BCs, 54 distant metastases, and three
deaths from BC. The estimated 5-year DFS rate for
the Ki67Medium group (93%) was significantly less than
for the Ki67Low group (97%; log-rank P = 0.003), but
significantly better than for the Ki67High group (85%,
log-rank P = 0.014; Fig. 1).
Our univariate analysis associated age younger than
35 years, tumor >2 cm, lymph node involvement, posi-
tive LVI status, grade III disease, higher Ki67-LI group,
and surgical approach (mastectomy vs. BCS) with worse
prognoses (Table 2). In multivariate analysis, the Ki67-LI
groups were a significant independent predictor for DFS
after adjusting for clinicopathological parameters and
treatments (Table 2).
To refine prognostication for the Ki67Medium group, we
investigated the value of conventional clinical parameters.
Interestingly, these factors, including tumor size >2 cm,
lymph node status (N1 vs. N0), and grade III disease, had
significant prognostic value in univariate and multivariate
analyses of DFS for the Ki67Medium group (Table 3), but not
the Ki67Lowor Ki67High groups (Additional file 1: Table S1
and Additional file 2: Table S2).
Discussion
In this study, we investigated clinicopathologic charac-
teristics and prognoses of the three risk levels among pa-
tients with ER+/HER2− BCs, according to the most
recent consensus from the 2015 St Gallen Conference,
which focuses on local laboratory Ki67-LIs. To our
knowledge, such an evaluation based on the 2015 St
Gallen Breast Cancer Conference consensus has never
been published before.
Ki67 is a nuclear protein expressed in all active phases
of the cell cycle except resting phase G0 [11]. Therefore,
it can be used as an alternative marker of proliferation
by IHC assessment in many malignancies, including BC.
Ki67 has been extensively evaluated in both research
and clinical settings [12], and clearly offers robust prog-
nostic and predictive information [13, 14]. The St Gallen
International BC Conferences have recommended using
Fig. 1 Disease-free survival according to Ki67-LI level group by Kaplan-Meier analysis
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Ki67-LI to tailor treatment in ER+/HER2− BCs from
2009 to 2015 [7–9, 15]. However, our understanding of
Ki67 has expanded, including its clinical value and
optimal cut-off point. The 2009 St Gallen consensus
suggested Ki67-LI as a proliferation marker in choosing
appropriate systemic treatment, categorizing it by three
levels: low (≤15%), intermediate (16–30%), or high
(>30%) [15]. After comparing Ki67-LI with PAM50 in-
trinsic subtyping, Cheang et al. suggested a cut-off point
of 14% to distinguish luminal B from luminal A subtype
in ER+/HER2− BCs [16]. The 2011 St Gallen Conference
then endorsed a 14% cut-off point between luminal A
and B tumors [7]. Subtyping can be used to shape
decisions about the use of cytotoxic chemotherapy for
luminal BCs [7, 8]. Luminal A disease generally requires
only endocrine therapy, whereas chemotherapy is usually
indicated for luminal B diseases. In 2013, the cut-off
point was increased to 20% by the St Gallen panel
[8]. Meta-analysis also showed diverse cut-off points
of Ki67-LI ranging from 3.5 to 34% with various
definitions [13]. A recent meta-analysis of more than
60,000 patients confirmed the prognostic value of Ki67-LI,
and found 25% to be an optimal cut-off point [17].
At the most recent St Gallen Conference, in 2015, the
panel recognized the controversy of using Ki67-LI by
IHC assessment for clinical decisions [9]. The previous
efforts of finding a universal optimal cut-off point of
Ki67 might have been in vain, as Ki67 presents as a con-
tinuum. Clinicians should therefore be cautious when using
a single cut-off point to dichotomize Ki67 scores [6, 18].
Particularly, reproducibility across laboratories has proven
to be unacceptably poor, which is the major obstacle
for its clinical use [19]. Because of this, the American
Society of Clinical Oncology (ASCO) and NCCN do
not currently recommend Ki67 as a routine required
marker in clinical practice ([20], https://www.nccn.org/
professionals/physician_gls/pdf/breast.pdf). With the goal
of harmonizing methodology, the International Ki67
in Breast Cancer Working Group proposed guidelines
for Ki67 assessment [12]. However, the effect on actual
Table 2 Results of disease-free survival analysis by Cox proportional hazards model for the ER+/HER2− tumors, n = 939
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (years)
35–50 vs < 35 0.386 0.196 0.763 0.006 0.342 0.170 0.687 0.003
51–65 vs < 35 0.477 0.238 0.959 0.038 0.454 0.220 0.936 0.032
> 65 vs < 35 0.378 0.140 1.021 0.055 0.274 0.080 0.938 0.039
pT
T2 vs T1 2.162 1.348 3.468 0.001 1.731 1.054 2.844 0.030
T3 vs T1 4.654 1.948 11.118 0.001 3.219 1.288 8.045 0.012
N
N1 vs N0 1.826 1.173 2.844 0.008 1.797 1.007 3.207 0.047
LVI
positive vs negative 1.831 1.099 3.048 0.020 1.332 0.776 2.284 0.298
Grade
III vs I/II 2.890 1.808 4.619 <0.001 1.785 1.059 3.010 0.030
Ki67(%)
10–30 vs ≤10 2.859 1.336 6.116 0.007 2.835 1.312 6.126 0.008
≥ 30 vs ≤10 5.394 2.732 10.651 <0.001 4.239 2.057 8.735 <0.001
PgR(%)
< 20 vs ≥20 1.273 0.778 2.083 0.336 0.799 0.472 1.355 0.405
Surgery
Mastectomy vs BCS 1.658 1.065 2.581 0.025 0.941 0.472 1.874 0.862
Chemotherapy
No vs Yes 0.731 0.376 1.419 0.354 1.430 0.620 3.298 0.402
Radiotherapy
No vs Yes 1.291 0.803 2.074 0.292 2.157 0.950 4.894 0.066
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practice is less than optimal [21, 22]. Studies [21] and new
image analyses [23] that aim to increase concordance in
Ki67 scoring are still under development.
The 2015 St Gallen consensus panel recommended
interpreting Ki67-LI with local laboratory values [9],
which was also suggested by the European Society for
Medical Oncology (ESMO) clinical practice guidelines
[24]. In our study, median Ki67-LI was 25% for all tu-
mors and 20% for the ER+/HER2− subset. The two
values reported by Cserni study were 17 and 14%, re-
spectively [22]. Although the numerical gaps between
these two centers were only 8 and 6% for two different
patient sets, the numerous patients within this range
should not be ignored. Of the 939 ER+/HER2− cases in
our study, 214 (22.8%) had Ki67-LIs between 14 and
20%. Our Ki67-LI values also intensively clustered at
those ending with 5 or 0 (91.4% for all tumors and
88.3% for ER+/HER2− subset), as did those in the Cserni
study [22]. This finding reflects a common practice of
pathologists. In our 939 cases of ER+/HER2− tumors,
none of the Ki67-LIs were valued at 14%, and only four
cases at 12% or 13%, but 103 patients—11%—had Ki67-
LIs of 15%. In light of this pattern, the widely used 14%
cut-off point recommended by the 2011 St Gallen
Conference seems unreasonable.
When ER+/HER2− cases were stratified into three
levels by median Ki67-LI value 20%, the Ki67High group
(≥30%) had less-favorable clinicopathologic characteris-
tics, including the highest percentages of patients youn-
ger than 35 years, large tumors, high histology grades,
and low or negative PgR. The Ki67Low group (≤10%) had
some favorable features, and features of the Ki67Medium
group (10–30%) were between the other two groups.
These findings confirmed the validity of these Ki67
groupings from a clinicopathologic perspective. The
three groups differed significantly in DFS (P < 0.001),
with the Ki67Low group having the longest DFS and the
Ki67High group the shortest.
To refine prognostication within the Ki67Medium group,
we examined other conventional diagnostic factors. We
found that tumors larger than 2 cm, lymph node in-
volvement, and grade III disease were all associated with
poorer prognoses in the Ki67Medium group after adjusting
for treatments; however, these parameters had no prog-
nostic significance in Ki67High and Ki67Low groups. It is
difficult to standardize scores for patients with Ki67Medium
LIs, as they suffer from the highest variability [25, 26].
Accordingly, when making clinical decisions about the in-
clusion of cytotoxic chemotherapy for ER+/HER2− BCs
with intermediate Ki67-LI, other conventional parameters
Table 3 Results of disease-free survival analysis by Cox proportional hazards model for the Ki67Medium group
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (years)
35–50 vs < 35 0.865 0.110 6.797 0.891 0.872 0.098 7.723 0.902
51–65 vs < 35 0.938 0.115 7.675 0.952 1.218 0.130 11.454 0.863
> 65 vs < 35 0.994 0.090 11.048 0.996 0.605 0.028 13.007 0.748
pT
T2 vs T1 2.778 1.068 7.229 0.036 2.781 1.004 7.701 0.049
T3 vs T1 9.961 0.036 37.642 0.001 6.421 1.226 33.629 0.028
N
N1 vs N0 3.087 1.255 7.589 0.014 4.572 1.500 13.933 0.008
LVI
positive vs negative 2.476 0.979 6.263 0.048 1.434 0.517 3.977 0.488
Grade
III vs I/II 4.437 1.828 10.770 0.001 4.468 1.650 12.104 0.003
PgR(%)
< 20 vs ≥20 0.714 0.209 2.437 0.591 0.602 0.159 2.274 0.454
Surgery
Mastectomy vs BCS 2.455 1.001 6.020 0.050 0.452 0.108 1.890 0.277
Chemotherapy
No vs Yes 0.556 0.129 2.396 0.431 1.048 0.116 9.452 0.967
Radiotherapy
No vs Yes 2.042 0.830 5.021 0.120 8.786 1.779 43.388 0.008
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may provide more valuable information rather than
Ki67-LI, or, alternatively, multigene assays [26]. However,
multigene assays are not readily available worldwide owing
to high cost and technical requirements. The prognosis
significance of chemotherapy was not shown in analyses
for the Ki67Medium group. This result may be due to the
low percentage of patients without chemotherapy. Further
researches are needed to study the prognosis significance
of treatments for the Ki67Medium group.
PgR status was adopted to define luminal B breast tu-
mors by the 2013 St Gallen consensus, using the cut-off
point of 20% proposed by Prat et al. [27]. However, this
cut-off for PgR had no prognostic significance for DFS
in our ER+/HER2− cohort. Maisonneuve et al. [28]. also
found that PgR < 20% was not associated with poorer
outcomes for all tumors, but only for patients with
Ki67-LI of 14–20% in their study cohort. ESMO empha-
sized the importance of laboratory quality assurance in
recommending the cut-off of 20%. The cut-off point of
PgR still needs more study, just as Ki67-LI does.
This study has some limitations. First, this was a
single-institution retrospective study, and its results
might not be directly applicable to other institutions. Be-
fore putting these results into clinical practice, other in-
stitution should verify them with their own laboratory
data. In addition, the follow-up period of this cohort was
relatively short considering that in the ER+/HER2− subset,
most cases of recurrence—let alone death—occur at least
5 years later [29, 30]. For this reason, we did not analyze
overall survival in this study.
Conclusions
We have evaluated distribution of Ki67-LI at an Asian
institution and confirmed its validity as a risk factor
among ER+/HER2− BCs according to the 2015 St Gallen
consensus. For patients with clearly very low or very
high Ki67-LIs in early-stage BCs, the importance of Ki67
in clinical decisions is rather straightforward. However,
for patients whose Ki67-LIs are in a medium range,
diagnostic parameters including tumor size, lymph node
involvement, and grade might provide significant clues.
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